Is Gilead Sciences, Inc. Stock A Buy Ahead Of Second Quarter Earnings
July 22, 2016 at 15:32 PM EDT
For Gilead Sciences, analysts are expecting $3.02 in earnings and revenues of $7.8 billion. Guidance again will be key. HCV sales have been under pressure which is the reason for the stagnant share price. Does Gilead have a solution?.
